PMID- 25639711 OWN - NLM STAT- MEDLINE DCOM- 20151127 LR - 20191023 IS - 1530-0277 (Electronic) IS - 0145-6008 (Print) IS - 0145-6008 (Linking) VI - 39 IP - 3 DP - 2015 Mar TI - The relationship of alcohol use disorders and depressive symptoms to tryptophan metabolism: cross-sectional data from a Nepalese alcohol treatment sample. PG - 514-21 LID - 10.1111/acer.12651 [doi] AB - BACKGROUND: Activation of the kynurenine pathway of tryptophan metabolism results in increased production of potentially depressogenic tryptophan catabolites and a reduction in tryptophan availability for serotonin synthesis. As alcohol consumption affects tryptophan metabolism and disposition, we determined serum levels of tryptophan, kynurenine, and an index of tryptophan degradation (kynurenine/tryptophan ratio) in patients with alcohol-use disorder (AUD) and compared their levels considering abstinence duration, AUD severity, and comorbid depression. METHODS: The study sample included 169 AUD inpatients from 8 alcohol treatment facilities in Kathmandu, Nepal. The Composite International Diagnostic Interview was administered to generate the AUD diagnosis. The Alcohol Use Disorder Identification Test (AUDIT) captured AUD severity and patterns of alcohol use. The Hopkins Symptom Checklist-25 was used to reveal current depressive symptoms. Serum kynurenine and tryptophan levels were determined by high-performance liquid chromatography, and tryptophan degradation was measured by KT ratio (kynurenine/tryptophan x 10(3)). RESULTS: Patients with above average AUDIT scores had higher mean serum levels of kynurenine (2.1 muM +/- 0.7 vs. 1.8 muM +/- 0.6, p = 0.006) and KT ratios (48.6 +/- 17.6 vs. 40.4 +/- 14.3, p = 0.002) than those with below average scores. Patients with current depressive symptoms had higher mean tryptophan concentrations (49.9 muM +/- 13 vs. 45.7 muM +/- 14.1, p = 0.047) and lower KT ratios (41.4 +/- 14 vs. 47.5 +/- 17.6, p = 0.028) compared to patients whose reported depressive symptoms were below the standard cutoff. Higher tryptophan levels and lower KT ratios in the depressed group were specific to patients with longer abstinence and higher AUD severity. CONCLUSIONS: Depression-related deregulation in tryptophan metabolism was found to depend on length of abstinence and on AUD severity. Together, results suggest that in AUD populations, peripheral tryptophan metabolism is subject to interactions between AUD severity and depressive symptoms. CI - Copyright (c) 2015 by the Research Society on Alcoholism. FAU - Neupane, Sudan Prasad AU - Neupane SP AD - SERAF-Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway. FAU - Lien, Lars AU - Lien L FAU - Martinez, Priscilla AU - Martinez P FAU - Hestad, Knut AU - Hestad K FAU - Bramness, Jorgen G AU - Bramness JG LA - eng GR - P50 AA005595/AA/NIAAA NIH HHS/United States GR - T32 AA007240/AA/NIAAA NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150130 PL - England TA - Alcohol Clin Exp Res JT - Alcoholism, clinical and experimental research JID - 7707242 RN - 0 (Biomarkers) RN - 343-65-7 (Kynurenine) RN - 8DUH1N11BX (Tryptophan) SB - IM MH - Adult MH - Alcohol-Related Disorders/*blood/diagnosis/*epidemiology MH - Biomarkers/blood MH - Cross-Sectional Studies MH - Depression/*blood/diagnosis/*epidemiology MH - Female MH - Humans MH - Kynurenine/blood MH - Male MH - Middle Aged MH - Nepal/epidemiology MH - Treatment Outcome MH - Tryptophan/*blood/metabolism MH - Young Adult PMC - PMC4348238 MID - NIHMS658792 OTO - NOTNLM OT - Alcohol OT - Comorbidity OT - Depression OT - Kynurenine Pathway OT - Tryptophan Metabolism EDAT- 2015/02/03 06:00 MHDA- 2015/12/15 06:00 PMCR- 2016/03/01 CRDT- 2015/02/03 06:00 PHST- 2014/10/01 00:00 [received] PHST- 2014/12/03 00:00 [accepted] PHST- 2015/02/03 06:00 [entrez] PHST- 2015/02/03 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] PHST- 2016/03/01 00:00 [pmc-release] AID - 10.1111/acer.12651 [doi] PST - ppublish SO - Alcohol Clin Exp Res. 2015 Mar;39(3):514-21. doi: 10.1111/acer.12651. Epub 2015 Jan 30.